Please provide your email address to receive an email when new articles are posted on . The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only ...

Advances Amgen's Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG IgG4-RD can occur in multiple organs and lead to fibrosis and ...

They could be doing better, at least in Europe. Data from 14 centers revealed moderate adherence to treatment guidelines, partial adherence to follow-up assessment, and poor adherence to monitoring ...

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think the most important thing to know is ...

—They could be doing better, at least in Europe. Data from 14 centers revealed moderate adherence to treatment guidelines, partial adherence to follow-up assessment, and poor adherence to monitoring ...

Flare-free, treatment-free complete remission and flare-free, glucocorticoid-free complete remission occurred in more participants in the inebilizumab group than the placebo group. (HealthDay News) — ...

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the therapeutic indication of Uplizna (inebilizumab, Amgen Europe) to include ...

The patient in the current case report showed manifestations of both AAV and IgG4-RD; his improvement linked to steroid/cyclophosphamide treatment underscores the need for integrated diagnosis and ...

Sanofi SNY announced that the European Medicines Agency (EMA) has granted orphan drug designation to its investigational BTK inhibitor, rilzabrutinib, for treating IgG4-related disease (IgG4-RD). IgG4 ...

Renal disease is a rare but potentially severe manifestation of IgG4-RD. An elderly man with immunoglobulin G4-related disease (IgG4-RD) with kidney involvement and monoclonal gammopathy was ...

Advances Amgen (AMGN)'s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, Calif., April 3, 2025 /PRNewswire/ -- ...